Cytek Biosciences, Inc. Shares Outstanding 2020–2025
Cytek Biosciences, Inc. reported 128.6M of shares outstanding for fiscal 2025. That was 0.5% lower than fiscal 2024. Compared with fiscal 2020, the change was +311.5%. A falling share count is consistent with net buybacks exceeding issuance over the period, though the filing should be checked for the components.
| Fiscal year | Shares Outstanding | Change (YoY) |
|---|---|---|
| FY 2025 | 128.6M | -0.5% |
| FY 2024 | 129.2M | -1.2% |
| FY 2023 | 130.7M | -3.4% |
| FY 2022 | 135.4M | +1.2% |
| FY 2021 | 133.7M | +328.1% |
| FY 2020 | 31.2M | — |
Source: Cytek Biosciences, Inc. SEC filings — balance sheet (10-K), split-adjusted. Computed deterministically; refreshed nightly (last updated August 2, 2026). Open CTKB 10-K filings at SEC EDGAR · Methodology · Download CSV.
How to read this history
Cytek Biosciences, Inc. reported 128.6M of shares outstanding for fiscal 2025. That was 0.5% lower than fiscal 2024. Compared with fiscal 2020, the change was +311.5%. A falling share count is consistent with net buybacks exceeding issuance over the period, though the filing should be checked for the components. Values remain missing when the cached filing does not disclose a comparable line item; they are never estimated. Stock splits, reorganizations and fiscal-calendar changes can reduce comparability.
Prepared and reviewed by the stockportfolio.pro research desk. Corrections: support@stockportfolio.pro.
See the full picture for Cytek Biosciences, Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeCytek Biosciences, Inc. — frequently asked questions
What is Cytek Biosciences, Inc.'s shares outstanding?
Cytek Biosciences, Inc. (CTKB) reported shares outstanding of 128.6M for fiscal year 2025, per its SEC filings.
How has Cytek Biosciences, Inc.'s shares outstanding changed over time?
Between fiscal 2020 and 2025, CTKB's shares outstanding grew at roughly 32.7% per year (compound annual rate), from 31.2M to 128.6M.
Where does this data come from?
Figures are computed from Cytek Biosciences, Inc.'s official SEC filings (balance sheet (10-K), split-adjusted), refreshed nightly. Not investment advice.
More CTKB financial history
Full CTKB fundamentals page → · Analyze shares outstanding with a free tool → · Research guide & leaders → · All 1,500+ companies →